Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 320

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial

Open access
Schweitzer, Paula K., Rosenberg, Russell, Zammit, Gary K., Gotfried, Mark, Chen, Dan, Carter, Lawrence P., Wang, Hao, Lu, Yuan, Black, Jed, Malhotra, Atul, Strohl, Kingman P., Blackman, Adam, George, Charles, Shapiro, Colin, Shapiro, Colin, Benes, Heike, Fietze, Ingo, Mayer, Geert, Young, Peter, Lammers, Gert Jan, Ahmed, Mansoor, Ajayi, Akinyemi, Andry, James, Artal, Roy, Bastani, Bijan, Bogan, Richard, Corser, Bruce, Drake, Christopher, Emsellem, Helene, Erman, Milton, Feldman, Neil, Foldvary, Nancy, Gotfried, Mark, Hudson, John, Krahn, Lois, Lorch, Daniel, Malhotra, Atul, Maynard, James, Mignot, Emmanuel, Neeb, Michael, Ojile, Joseph, Perkins, Alvin Thomas, Rosenberg, Russell, Roy, Asim, Sahota, Pradeep, Sangal, R. Bart, Schreiber, Andrew, Schweitzer, Paula, Steele, Ralph, Stern, Thomas, Stern, Thomas, Stolz, Sarah, Strohl, Kingman, Swick, Todd, Swick, Todd J., Thein, Stephen G., Thomas, Robert, Thorpy, Michael, Weaver, Terri, Wilks, Kerri, Winslow, David, Wylie, Paul, Zammit, Gary, Zee, Phyllis·2019·American Journal of Respiratory and Critical Care Medicine

Abstract

Abstract Rationale Primary treatment of obstructive sleep apnea can be accompanied by a persistence of excessive sleepiness despite adherence. Furthermore, effectiveness of sleep apnea treatment is limited by poor adherence. Currently available pharmacologic options for the treatment of sleepiness in this population are limited. Objectives To evaluate the efficacy and safety of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor with robust wake-promoting effects, for the treatment of excessive sleepiness in participants with obstructive sleep apnea with current or prior sleep apnea treatment. Methods This was a double-blind, randomized, placebo-controlled, parallel-group, 12-week trial comparing solriamfetol, 37.5, 75, 150, and 300 mg, with placebo. Measurements and Main Results Of 476 randomized participants, 459 were included in the prespecified efficacy analyses. Coprimary endpoints (Maintenance of Wakefulness Test sleep latency and Epworth Sleepiness Scale score) were met at all solriamfetol doses (P < 0.05), with dose-dependent effects observed at Week 1 maintained over the study duration. All doses except 37.5 mg resulted in higher percentages of participants reporting improvement on Patient Global Impression of Change (key secondary endpoint; P < 0.05). Adverse events were reported in 47.9% of placebo- and 67.9% of solriamfetol-treated participants; five participants experienced serious adverse events (two [1.7%] placebo, three [0.8%] solriamfetol); none were deemed related to study drug. The most common adverse events with solriamfetol were headache (10.1%), nausea (7.9%), decreased appetite (7.6%), anxiety (7.0%), and nasopharyngitis (5.1%). Conclusions Solriamfetol significantly increased wakefulness and reduced sleepiness in participants with obstructive sleep apnea and excessive sleepiness; most adverse events were mild or moderate in severity. Clinical trial registered with www.clinicaltrials.gov (NCT02348606) and www.eudract.ema.europa.eu (EudraCT 2014-005514-31).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1164/rccm.201806-1100oc

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Cited by

See all 320

Metadata

Authors
Schweitzer, P. K., Rosenberg, R., Zammit, G. K., Gotfried, M., Chen, D., Carter, L. P., Wang, H., Lu, Y., Black, J., Malhotra, A., Strohl, K. P., Blackman, A., George, C., Shapiro, C., Shapiro, C., Benes, H., Fietze, I., Mayer, G., Young, P., Lammers, G. J., Ahmed, M., Ajayi, A., Andry, J., Artal, R., Bastani, B., Bogan, R., Corser, B., Drake, C., Emsellem, H., Erman, M., Feldman, N., Foldvary, N., Gotfried, M., Hudson, J., Krahn, L., Lorch, D., Malhotra, A., Maynard, J., Mignot, E., Neeb, M., Ojile, J., Perkins, A. T., Rosenberg, R., Roy, A., Sahota, P., Sangal, R. B., Schreiber, A., Schweitzer, P., Steele, R., Stern, T., Stern, T., Stolz, S., Strohl, K., Swick, T., Swick, T. J., Thein, S. G., Thomas, R., Thorpy, M., Weaver, T., Wilks, K., Winslow, D., Wylie, P., Zammit, G., & Zee, P.
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2019-06-01
Volume
199
Issue
11
Pages
1421-1431
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W2905201451
Cited by
320
References
44
FWCI
33.11
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial. https://app.cochat.ai/papers/10.1164/rccm.201806-1100oc
The paper
Schweitzer, P. K., Rosenberg, R., Zammit, G. K., Gotfried, M., Chen, D., Carter, L. P., Wang, H., Lu, Y., Black, J., Malhotra, A., Strohl, K. P., Blackman, A., George, C., Shapiro, C., Shapiro, C., Benes, H., Fietze, I., Mayer, G., Young, P., . . . Zee, P. (2019). Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201806-1100oc

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.